Opevesostat
Opevesostat is an experimental small-molecule drug from Merck Sharp & Dohme in phase 3 trials for prostate cancer, with its target not yet stated publicly.
Overview
Opevesostat (MK-5684, ODM-208) is a small-molecule drug developed by Merck Sharp & Dohme. Its molecular target is not stated in the ClinicalTrials.gov intervention record, and OnCo has not confirmed one from the sponsor's pipeline page. It is the investigational product in 5 recruiting or active industry-led phase 2 and phase 3 interventional cancer trials, including phase 3 studies NCT06136624 (Study of Opevesostat (MK-5684) Versus Alternative NHA in mCRPC (MK-5684-003)) and NCT06136650 (A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004)), in prostate cancer. The largest, NCT06136650, plans to enrol 1314 participants with primary completion expected 2028-05-10. Status reflects the highest phase registered on ClinicalTrials.gov at the 2026-09-11 check; no efficacy results are recorded here.
- AmivantamabApproved
- CamizestrantApproved
- Comprehensive genomic profilingStandard of care
- Liquid biopsy (ctDNA)Standard of care
- LorlatinibApproved
- MRD / molecular residual disease testingEstablished
- ADC payload neutralisersPhase 1
- BGB-16673Phase 3
- Bispecific ADCPhase 3
- BRUIN CLL-321Positive
- CaDAnCe-304Recruiting
- CIRCULATE-Japan (GALAXY / VEGA / ALTAIR)Active
- A clone report from blood at every treatment cycle
- A fast route to the matched drug when it is licensed for another cancer
- A multi-cancer platform trial of adaptive (dose-holiday) therapy
- A national rapid research autopsy network for end-stage cancer
- A standard evolvability score for every tumour
- A standing platform trial that assigns treatment by how the tumour escaped
Background: ADC sequencing, Antigen escape (antigen loss, lineage switch), BCG-unresponsive, Castration-resistant prostate cancer (CRPC), Circulating tumour DNA (ctDNA). Also on OnCo: Resistance atlas · Lines of therapy.
Trials
topTrials recruiting now
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Landmark trials
Latest papers
topQuery for this drug: (TITLE:"Opevesostat" OR ABSTRACT:"Opevesostat" OR TITLE:"MK-5684" OR ABSTRACT:"MK-5684" OR TITLE:"ODM-208" OR ABSTRACT:"ODM-208") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Opevesostat, not a curated reading list.
Similar pages
not linked directly; found by shared links- TreatmentBomedemstat
Shares Merck & Co. (MSD) and the tags pipeline, ctgov-ingest.
- TreatmentFPI-2265
Shares Prostate cancer and the tags pipeline, ctgov-ingest.
- TreatmentAZD6621
Shares Prostate cancer and the tags pipeline, ctgov-ingest.
- TreatmentAZD9750
Shares Prostate cancer and the tags pipeline, ctgov-ingest.
- TreatmentQLH12016
Shares Prostate cancer and the tags pipeline, ctgov-ingest.
- TreatmentXNW5004
Shares Prostate cancer and the tags pipeline, ctgov-ingest.
- TreatmentRinzimetostat
Shares Prostate cancer and the tags pipeline, ctgov-ingest.
- TreatmentBMS-986365
Shares Prostate cancer and the tags pipeline, ctgov-ingest.